|
1.Perl DP (1985) Relationship of aluminum to Alzheimer''s disease. Environ Health Perspect 63: 149-153 2.Chen SM, Fan CC, Chiue MS, Chou C, Chen JH, et al. (2013) Hemodynamic and neuropathological analysis in rats with aluminum trichloride-induced Alzheimer''s disease. PLoS One 8: e82561 3.Kaur A, Gill KD (2006) Possible peripheral markers for chronic aluminium toxicity in Wistar rats. Toxicol Ind Health 22: 39-46 4.Bondy SC (2014) Prolonged exposure to low levels of aluminum leads to changes associated with brain aging and neurodegeneration. Toxicology 315: 1-7 5.Kawahara M, Kato-Negishi M (2011) Link between Aluminum and the Pathogenesis of Alzheimer''s Disease: The Integration of the Aluminum and Amyloid Cascade Hypotheses. Int J Alzheimers Dis 2011: 276393 6.Maurer K, Volk S, Gerbaldo H (1997) Auguste D and Alzheimer''s disease. Lancet 349: 1546-1549. 7.Kraepelin E (2012) The Real “Inventor” of Alzheimer’s Disease and Pioneer of Modern Psychiatry. 8.Glenner GG, Wong CW (1984) Alzheimer''s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890. 9.Mukhin VN (2013) [The role of the basal forebrain cholinergic dysfunction in pathogenesis of declarative memory disorder in Alzheimer''s disease]. Ross Fiziol Zh Im I M Sechenova 99: 674-681 10.Anand P, Singh B (2013) A review on cholinesterase inhibitors for Alzheimer''s disease. Arch Pharm Res 36: 375-399 11.Parsons MP, Raymond LA (2014) Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 82: 279-293 12.Seeman P, Seeman N (2011) Alzheimer''s disease: beta-amyloid plaque formation in human brain. Synapse 65: 1289-1297 13.Meraz-Rios MA, Franco-Bocanegra D, Toral Rios D, Campos-Pena V (2014) Early onset Alzheimer''s disease and oxidative stress. Oxid Med Cell Longev 2014: 375968 14.Wen ZY, Xie JX, Guan ZW, Sun DG, Yao WJ, et al. (2000) A study of hemorheological behaviour for patients with Alzheimer''s disease at the early stages. Clinical Hemorheology and Microcirculation 22: 261-266. 15.Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer''s disease. Trends Pharmacol Sci 12: 383-388. 16.Kalaria RN (1996) Cerebral vessels in ageing and Alzheimer''s disease. Pharmacol Ther 72: 193-214. 17.Solerte SB, Ceresini G, Ferrari E, Fioravanti M (2000) Hemorheological changes and overproduction of cytokines from immune cells in mild to moderate dementia of the Alzheimer''s type: adverse effects on cerebromicrovascular system. Neurobiol Aging 21: 271-281. 18.de la Torre JC, Mussivand T (1993) Can disturbed brain microcirculation cause Alzheimer''s disease? Neurol Res 15: 146-153. 19.Ajmani RS, Metter EJ, Jaykumar R, Ingram DK, Spangler EL, et al. (2000) Hemodynamic changes during aging associated with cerebral blood flow and impaired cognitive function. Neurobiology of Aging 21: 257-269. 20.de la Torre JC (1994) Impaired brain microcirculation may trigger Alzheimer''s disease. Neurosci Biobehav Rev 18: 397-401. 21.Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, et al. (1997) Brain infarction and the clinical expression of Alzheimer disease - The nun study. Jama-Journal of the American Medical Association 277: 813-817. 22.Crapper DR, Krishnan SS, Quittkat S (1976) Aluminium, neurofibrillary degeneration and Alzheimer''s disease. Brain 99: 67-80. 23.Erazi H, Sansar W, Ahboucha S, Gamrani H (2010) Aluminum affects glial system and behavior of rats. C R Biol 333: 23-27. 24.Rondeau V, Commenges D, Jacqmin-Gadda H, Dartigues JF (2000) Relation between aluminum concentrations in drinking water and Alzheimer''s disease: an 8-year follow-up study. Am J Epidemiol 152: 59-66. 25.Flaten TP (2001) Aluminium as a risk factor in Alzheimer''s disease, with emphasis on drinking water. Brain Research Bulletin 55: 187-196. 26.McLachlan DR, Kruck TP, Lukiw WJ, Krishnan SS (1991) Would decreased aluminum ingestion reduce the incidence of Alzheimer''s disease? CMAJ 145: 793-804. 27.Hantson P, Mahieu P, Gersdorff M, Sindic C, Lauwerys R (1995) Fatal encephalopathy after otoneurosurgery procedure with an aluminum-containing biomaterial. J Toxicol Clin Toxicol 33: 645-648. 28.Jack R, Rabin PL, McKinney TD (1983) Dialysis encephalopathy: a review. Int J Psychiatry Med 13: 309-326. 29.Bilkei-Gorzo A (1993) Neurotoxic effect of enteral aluminium. Food Chem Toxicol 31: 357-361. 30.Zatta P, Ibn-Lkhayat-Idrissi M, Zambenedetti P, Kilyen M, Kiss T (2002) In vivo and in vitro effects of aluminum on the activity of mouse brain acetylcholinesterase. Brain Res Bull 59: 41-45. 31.Kim Y, Olivi L, Cheong JH, Maertens A, Bressler JP (2007) Aluminum stimulates uptake of non-transferrin bound iron and transferrin bound iron in human glial cells. Toxicol Appl Pharmacol 220: 349-356. 32.Zhang ZJ, Qian YH, Hu HT, Yang H, Yang GD (2003) The herbal medicine Dipsacus asper Wall extract reduces the cognitive deficits and overexpression of beta-amyloid protein induced by aluminum exposure. Life Sciences 73: 2443-2454. 33.Miu AC, Andreescu CE, Vasiu R, Olteanu AI (2003) A behavioral and histological study of the effects of long-term exposure of adult rats to aluminum. Int J Neurosci 113: 1197-1211. 34.Campbell A, Bondy SC (2000) Aluminum induced oxidative events and its relation to inflammation: a role for the metal in Alzheimer''s disease. Cell Mol Biol (Noisy-le-grand) 46: 721-730. 35.Xu H, Greengard P, Gandy S (1995) Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein. J Biol Chem 270: 23243-23245. 36.Perl DP, Brody AR (1980) Alzheimer''s disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 208: 297-299. 37.Fasman GD, Perczel A, Moore CD (1995) Solubilization of beta-amyloid-(1-42)-peptide: reversing the beta-sheet conformation induced by aluminum with silicates. Proc Natl Acad Sci U S A 92: 369-371. 38.Savory J, Herman MM, Ghribi O (2003) Intracellular mechanisms underlying aluminum-induced apoptosis in rabbit brain. J Inorg Biochem 97: 151-154. 39.Savory J, Rao JK, Huang Y, Letada PR, Herman MM (1999) Age-related hippocampal changes in Bcl-2:Bax ratio, oxidative stress, redox-active iron and apoptosis associated with aluminum-induced neurodegeneration: increased susceptibility with aging. Neurotoxicology 20: 805-817. 40.Guo GW, Liang YX (2001) Aluminum-induced apoptosis in cultured astrocytes and its effect on calcium homeostasis. Brain Res 888: 221-226. 41.Abubakar MG, Taylor A, Ferns GAA (2003) Aluminium administration is associated with enhanced hepatic oxidant stress that may be offset by dietary vitamin E in the rat. International Journal of Experimental Pathology 84: 49-54. 42.Di JW, Bi SP (2003) Aluminum ions accelerated the oxidative stress of copper-mediated melanin formation. Spectrochimica Acta Part a-Molecular and Biomolecular Spectroscopy 59: 3075-3083. 43.Sethi P, Jyoti A, Singh R, Hussain E, Sharma D (2008) Aluminium-induced electrophysiological, biochemical and cognitive modifications in the hippocampus of aging rats. Neurotoxicology 29: 1069-1079. 44.Platt B, Fiddler G, Riedel G, Henderson Z (2001) Aluminium toxicity in the rat brain: histochemical and immunocytochemical evidence. Brain Res Bull 55: 257-267. 45.Toledano A, Alvarez MI (2004) Lesions and dysfunctions of the nucleus basalis as Alzheimer''s disease models: general and critical overview and analysis of the long-term changes in several excitotoxic models. Curr Alzheimer Res 1: 189-214. 46.Gong QH, Wu Q, Huang XN, Sun AS, Nie J, et al. (2006) Protective effect of Ginkgo biloba leaf extract on learning and memory deficit induced by aluminum in model rats. Chin J Integr Med 12: 37-41. 47.Zhou Y, Qu ZQ, Zeng YS, Lin YK, Li Y, et al. (2012) Neuroprotective effect of preadministration with Ganoderma lucidum spore on rat hippocampus. Exp Toxicol Pathol 64: 673-680. 48.Sakurai K, Tokumaru AM, Nakatsuka T, Murayama S, Hasebe S, et al. (2014) Imaging spectrum of sporadic cerebral amyloid angiopathy: multifaceted features of a single pathological condition. Insights Imaging. 49.Tang YJ, Li Y, Wang S, Zhu MW, Sun YL, et al. (2013) The incidence of cerebral amyloid angiopathy in surgically treated intracranial hemorrhage in the Chinese population. Neurosurg Rev 36: 533-539. 50.Kumar-Singh S (2008) Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. Genes Brain Behav 7 Suppl 1: 67-82. 51.Chen YW, Gurol ME, Rosand J, Viswanathan A, Rakich SM, et al. (2006) Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology 67: 83-87. 52.Yamada M (2004) Cerebral amyloid angiopathy and gene polymorphisms. J Neurol Sci 226: 41-44. 53.Jellinger KA, Attems J (2005) Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci 229-230: 37-41. 54.Knudsen KA, Rosand J, Karluk D, Greenberg SM (2001) Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 56: 537-539. 55.Lieu CW, Lee SS, Wang SY (1992) The effect of Ganoderma lucidum on induction of differentiation in leukemic U937 cells. Anticancer Res 12: 1211-1215. 56.Zhang J, Wang G, Li H, Zhuang C, Mizuno T, et al. (1994) Antitumor active protein-containing glycans from the Chinese mushroom songshan lingzhi, Ganoderma tsugae mycelium. Biosci Biotechnol Biochem 58: 1202-1205. 57.Yu YH, Kuo HP, Hsieh HH, Li JW, Hsu WH, et al. (2012) Ganoderma tsugae Induces S Phase Arrest and Apoptosis in Doxorubicin-Resistant Lung Adenocarcinoma H23/0.3 Cells via Modulation of the PI3K/Akt Signaling Pathway. Evidence-Based Complementary and Alternative Medicine. 58.Wasser SP, Weis AL (1999) Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol 19: 65-96. 59.Gan KH, Fann YF, Hsu SH, Kuo KW, Lin CN (1998) Mediation of the cytotoxicity of lanostanoids and steroids of Ganoderma tsugae through apoptosis and cell cycle. Journal of Natural Products 61: 485-487. 60.Wu YW, Chen KD, Lin WC (2004) Effect of Ganoderma tsugae on chronically carbon tetrachloride-intoxicated rats. American Journal of Chinese Medicine 32: 841-850. 61.Yue GG, Fung KP, Tse GM, Leung PC, Lau CB (2006) Comparative studies of various ganoderma species and their different parts with regard to their antitumor and immunomodulating activities in vitro. J Altern Complement Med 12: 777-789 62.Wang GY, Zhang J, Mizuno T, Zhuang C, Ito H, et al. (1993) Antitumor Active Polysaccharides from the Chinese Mushroom Songshan-Lingzhi, the Fruiting Body of Ganoderma-Tsugae. Bioscience Biotechnology and Biochemistry 57: 894-900. 63.Gao XX, Wang BX, Fei XF, Zhang J, Gong YJ, et al. (2000) Effects of polysaccharides (FI0-c) from mycelium, of Ganoderma tsugae on proinflammatory cytokine production by THP-1 cells and human PBMC (II). Acta Pharmacologica Sinica 21: 1186-1192. 64.Lin KI, Kao YY, Kuo HK, Yang WB, Chou A, et al. (2006) Reishi polysaccharides induce immunoglobulin production through the TLR4/TLR2-mediated induction of transcription factor Blimp-1. Journal of Biological Chemistry 281: 24111-24123. 65.Kino K, Yamashita A, Yamaoka K, Watanabe J, Tanaka S, et al. (1989) Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. J Biol Chem 264: 472-478. 66.Kohda H, Tokumoto W, Sakamoto K, Fujii M, Hirai Y, et al. (1985) The biologically active constituents of Ganoderma lucidum (Fr.) Karst. Histamine release-inhibitory triterpenes. Chem Pharm Bull (Tokyo) 33: 1367-1374. 67.Kuok QY, Yeh CY, Su BC, Hsu PL, Ni H, et al. (2013) The triterpenoids of Ganoderma tsugae prevent stress-induced myocardial injury in mice. Mol Nutr Food Res 57: 1892-1896. 68.Ko HH, Hung CF, Wang JP, Lin CN (2008) Antiinflammatory triterpenoids and steroids from Ganoderma lucidum and G. tsugae. Phytochemistry 69: 234-239. 69.Mu D, Li C, Zhang X, Li X, Shi L, et al. (2013) Functions of the nicotinamide adenine dinucleotide phosphate oxidase family in Ganoderma lucidum: an essential role in ganoderic acid biosynthesis regulation, hyphal branching, fruiting body development, and oxidative-stress resistance. Environ Microbiol. 70.Kao PF, Wang SH, Hung WT, Liao YH, Lin CM, et al. (2012) Structural characterization and antioxidative activity of low-molecular-weights beta-1,3-glucan from the residue of extracted Ganoderma lucidum fruiting bodies. J Biomed Biotechnol 2012: 673764. 71.Deepalakshmi K, Mirunalini S, Krishnaveni M, Arulmozhi V (2013) In vitro and in vivo antioxidant potentials of an ethanolic extract of Ganoderma lucidum in rat mammary carcinogenesis. Chin J Nat Med 11: 621-627. 72.李端, 韓群, 楊香媛, 森昌夫, (1994). “靈芝對大鼠細胞膜流動性和封閉度的影響”. 靈芝的研究(一), 86-91. 73.Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, et al. (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer''s disease. New England Journal of Medicine 336: 1216-1222. 74.Mau JL, Tsai SY, Tseng YH, Huang SJ (2005) Antioxidant properties of methanolic extracts from Ganoderma tsugae. Food Chemistry 93: 641-649. 75.Sheng-Fa Tsai. (1998) “Studies on the anti-aging and anti-tumor effects of Ganoderma, a Chinese herbal medicine” 76.Southorn PA, Powis G (1988) Free radicals in medicine. I. Chemical nature and biologic reactions. Mayo Clin Proc 63: 381-389. 77.Turrens JF, Boveris A (1980) Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 191: 421-427. 78.Halliwell B. (1994) “Antioxidants: Sense or speculation?” Nutrition Today, 29, 15-19. 79.McCord JM, Fridovich I (1969) Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244: 6049-6055. 80.Kalaria RN (2010) Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev 68 Suppl 2: S74-87. 81.Smith MM, Chen PC, Li CS, Ramanujam S, Cheung AT (2009) Whole blood viscosity and microvascular abnormalities in Alzheimer''s Disease. Clin Hemorheol Microcirc 41: 229-239. 82.Cortes-Canteli M, Strickland S (2009) Fibrinogen, a possible key player in Alzheimer''s disease. Journal of Thrombosis and Haemostasis 7: 146-150. 83.Zlokovic BV (2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57: 178-201. 84.Chang CY, Liang HJ, Chow SY, Chen SM, Liu DZ (2007) Hemorheological mechanisms in Alzheimer''s disease. Microcirculation 14: 627-634. 85.Sabolovic D, Roudier M, Boynard M, Pautou C, Sestier C, et al. (1997) Membrane modifications of red blood cells in Alzheimer''s disease. J Gerontol A Biol Sci Med Sci 52: B217-220. 86.Bosman GJ, Janzing JG, Bartholomeus IG, De Man AJ, Zitman FG, et al. (1997) Erythrocyte aging characteristics in elderly individuals with beginning dementia. Neurobiol Aging 18: 291-295. 87.Lai CS, Yu MS, Yuen WH, So KF, Zee SY, et al. (2008) Antagonizing beta-amyloid peptide neurotoxicity of the anti-aging fungus Ganoderma lucidum. Brain Res 1190: 215-224. 88.J.-F., Stoltz,, et. al. (1999) “Hemorheology in Practice,Amsterdam Netherlands”, IOS Press 89.Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, et al. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82: 4245-4249. 90.Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, et al. (1987) The precursor of Alzheimer''s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736. 91.Revesz T, Holton JL, Lashley T, Plant G, Frangione B, et al. (2009) Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathologica 118: 115-130. 92.Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and Proteolytic Processing of APP. Cold Spring Harbor Perspectives in Medicine 2. 93.Kremer JJ, Sklansky DJ, Murphy RM (2001) Profile of changes in lipid bilayer structure caused by beta-amyloid peptide. Biochemistry 40: 8563-8571. 94.Wolfe MS (2001) Secretase targets for Alzheimer''s disease: identification and therapeutic potential. J Med Chem 44: 2039-2060. 95.Koudinov AR, Berezov TT, Koudinova NV (1998) Alzheimer''s amyloid beta and lipid metabolism: a missing link? FASEB J 12: 1097-1099. 96.Attems J (2005) Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol 110: 345-359. 97.Stopa EG, Butala P, Salloway S, Johanson CE, Gonzalez L, et al. (2008) Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype. Stroke 39: 814-821. 98.Yamamoto N, Tanida M, Ono Y, Kasahara R, Fujii Y, et al. (2014) Leptin inhibits amyloid beta-protein degradation through decrease of neprilysin expression in primary cultured astrocytes. Biochem Biophys Res Commun 445: 214-217. 99.Zhang H, Su YJ, Zhou WW, Wang SW, Xu PX, et al. (2014) Activated scavenger receptor a promotes glial internalization of abeta. PLoS One 9: e94197. 100.Gong QH, Wu Q, Huang XN, Sun AS, Shi JS (2005) Protective effects of Ginkgo biloba leaf extract on aluminum-induced brain dysfunction in rats. Life Sci 77: 140-148 101.Bor-Seng-Shu E, Hirsch R, Teixeira MJ, De Andrade AF, Marino R, Jr. (2006) Cerebral hemodynamic changes gauged by transcranial Doppler ultrasonography in patients with posttraumatic brain swelling treated by surgical decompression. J Neurosurg 104: 93-100. 102.Roher AE, Garami Z, Tyas SL, Maarouf CL, Kokjohn TA, et al. (2011) Transcranial doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer''s disease. Alzheimers Dement 7: 445-455. 103.李端等:靈芝對大鼠紅細胞超氧歧化&;#37238;(SOD)和膜蛋白組成的影響。靈芝的研究(一),p.92-95,1994 104.李端等: 靈芝對大鼠細胞膜流動性和封閉度的影響。靈芝的研究(一),p.86-91,1994 105.程彰華等: 靈芝對高血壓伴高血脂和腦血栓後遺症患者血液流變學的觀察。靈芝的研究 (一),p.100-103,1994 106.Verbeek MM, Kremer BP, Rikkert MO, Van Domburg PH, Skehan ME, et al. (2009) Cerebrospinal fluid amyloid beta(40) is decreased in cerebral amyloid angiopathy. Ann Neurol 66: 245-249 107.Govaerts L, Schoenen J, Bouhy D (2007) [Pathogenesis of Alzheimer''s disease: molecular and cellular mechanisms]. Rev Med Liege 62: 209-216. 108.Mattson MP, Begley JG, Mark RJ, Furukawa K (1997) Abeta25-35 induces rapid lysis of red blood cells: contrast with Abeta1-42 and examination of underlying mechanisms. Brain Res 771: 147-153. 109.Kumar-Singh S (2009) Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models. Int J Mol Sci 10: 1872-1895. 110.Schubert FR, Fainsod A, Gruenbaum Y, Gruss P (1995) Expression of the novel murine homeobox gene Sax-1 in the developing nervous system. Mech Dev 51: 99-114. 111.Van Lenten BJ, Wagner AC, Navab M, Fogelman AM (2001) Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 276: 1923-1929. 112.Wahlster L, Arimon M, Nasser-Ghodsi N, Post KL, Serrano-Pozo A, et al. (2013) Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer''s disease. Acta Neuropathol 125: 187-199. 113.Kawahara M, Kato-Negishi M (2011) Link between Aluminum and the Pathogenesis of Alzheimer''s Disease: The Integration of the Aluminum and Amyloid Cascade Hypotheses. Int J Alzheimers Dis 2011: 276393. 114.Bondy SC (2010) The neurotoxicity of environmental aluminum is still an issue. Neurotoxicology 31: 575-581. 115.Dudhgaonkar S, Thyagarajan A, Sliva D (2009) Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. Int Immunopharmacol 9: 1272-1280. 116.Yuen JW, Gohel MD (2008) The dual roles of Ganoderma antioxidants on urothelial cell DNA under carcinogenic attack. J Ethnopharmacol 118: 324-330. 117.Wachtel-Galor S, Choi SW, Benzie IF (2005) Effect of Ganoderma lucidum on human DNA is dose dependent and mediated by hydrogen peroxide. Redox Rep 10: 145-149. 118.Boh B, Berovic M, Zhang J, Zhi-Bin L (2007) Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 13: 265-301. 119.Li Z, Liu J, Zhao Y (2005) Possible mechanism underlying the antiherpetic activity of a proteoglycan isolated from the mycelia of Ganoderma lucidum in vitro. J Biochem Mol Biol 38: 34-40. 120.Bosman GJ, Bartholomeus IG, de Man AJ, van Kalmthout PJ, de Grip WJ (1991) Erythrocyte membrane characteristics indicate abnormal cellular aging in patients with Alzheimer''s disease. Neurobiol Aging 12: 13-18. 121.Mohanty JG, Shukla HD, Williamson JD, Launer LJ, Saxena S, et al. (2010) Alterations in the red blood cell membrane proteome in alzheimer''s subjects reflect disease-related changes and provide insight into altered cell morphology. Proteome Sci 8: 11. 122.Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, et al. (2000) Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 268: 750-756. 123.Nakagawa K, Kiko T, Miyazawa T, Sookwong P, Tsuduki T, et al. (2011) Amyloid beta-induced erythrocytic damage and its attenuation by carotenoids. FEBS Lett 585: 1249-1254. 124.Kanski J, Aksenova M, Butterfield DA (2002) The hydrophobic environment of Met35 of Alzheimer''s Abeta(1-42) is important for the neurotoxic and oxidative properties of the peptide. Neurotox Res 4: 219-223. 125.Choi BH (1995) Oxidative stress and Alzheimer''s disease. Neurobiol Aging 16: 675-678. 126.Ando K, Beppu M, Kikugawa K, Nagai R, Horiuchi S (1999) Membrane proteins of human erythrocytes are modified by advanced glycation end products during aging in the circulation. Biochem Biophys Res Commun 258: 123-127. 127.Schwartz RS, Madsen JW, Rybicki AC, Nagel RL (1991) Oxidation of spectrin and deformability defects in diabetic erythrocytes. Diabetes 40: 701-708. 128.van Rensburg SJ, Carstens ME, Potocnik FC, Aucamp AK, Taljaard JJ, et al. (1992) Membrane fluidity of platelets and erythrocytes in patients with Alzheimer''s disease and the effect of small amounts of aluminium on platelet and erythrocyte membranes. Neurochem Res 17: 825-829. 129.Christen Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71: 621S-629S. 130.Mosesson MW (2005) Fibrinogen and fibrin structure and functions. J Thromb Haemost 3: 1894-1904. 131.Ryu JK, McLarnon JG (2009) A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer''s disease brain. J Cell Mol Med 13: 2911-2925. 132.Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, et al. (2010) Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer''s disease. Neuron 66: 695-709. 133.Paul J, Strickland S, Melchor JP (2007) Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer''s disease. J Exp Med 204: 1999-2008. 134.Fiala A, Spall T, Diegelmann S, Eisermann B, Sachse S, et al. (2002) Genetically expressed cameleon in Drosophila melanogaster is used to visualize olfactory information in projection neurons. Curr Biol 12: 1877-1884. 135.van Oijen M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM (2005) Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36: 2637-2641. 136.Xu G, Zhang H, Zhang S, Fan X, Liu X (2008) Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. International Journal of Clinical Practice 62: 1070-1075. 137.Maeda A, Yamada M, Itoh Y, Otomo E, Hayakawa M, et al. (1993) Computer-assisted three-dimensional image analysis of cerebral amyloid angiopathy. Stroke 24: 1857-1864. 138.Solerte SB, Fioravanti M, Pascale A, Ferrari E, Govoni S, et al. (1998) Increased natural killer cell cytotoxicity in Alzheimer''s disease may involve protein kinase C dysregulation. Neurobiol Aging 19: 191-199. 139.Huberman M, Shalit F, Rothderi I, Gutman B, Brodie C, et al. (1994) Correlation of Cytokine Secretion by Mononuclear-Cells of Alzheimer Patients and Their Disease Stage. Journal of Neuroimmunology 52: 147-152. 140.Rankinen T, Hietanen E, Vaisanen S, Lehtio M, Penttila I, et al. (2000) Relationship between lipid peroxidation and plasma fibrinogen in middle-aged men. Thrombosis Research 99: 453-459. 141.Ogunshola OO, Antoniou X (2009) Contribution of hypoxia to Alzheimer''s disease: is HIF-1alpha a mediator of neurodegeneration? Cell Mol Life Sci 66: 3555-3563. 142.Peers C, Dallas ML, Boycott HE, Scragg JL, Pearson HA, et al. (2009) Hypoxia and neurodegeneration. Ann N Y Acad Sci 1177: 169-177. 143.Regeneration in the Peripheral Nervous System, Experimental Neurology, Volume 223, Issue 1, Pages 1-250(May 2010). 144.Chen GJ, Xu J, Lahousse SA, Caggiano NL, de la Monte SM (2003) Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. J Alzheimers Dis 5: 209-228. 145.Chiue MS (2013) Morphological and Functional Changes of Alzheimer’s Disease Animal Model Using MRI Techniques. Master thesis, National Taiwan University. 146.Cheung WM, Hui WS, Chu PW, Chiu SW, Ip NY (2000) Ganoderma extract activates MAP kinases and induces the neuronal differentiation of rat pheochromocytoma PC12 cells. FEBS Lett 486: 291-296. 147.Chu QP, Wang LE, Cui XY, Fu HZ, Lin ZB, et al. (2007) Extract of Ganoderma lucidum potentiates pentobarbital-induced sleep via a GABAergic mechanism. Pharmacol Biochem Behav 86: 693-698. 148.Gama Sosa MA, Gasperi RD, Rocher AB, Wang AC, Janssen WG, et al. (2010) Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer''s disease mutations. Am J Pathol 176: 353-368. 149.Davis J, Xu F, Deane R, Romanov G, Previti ML, et al. (2004) Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 279: 20296-20306. 150.Di Patre PL, Read SL, Cummings JL, Tomiyasu U, Vartavarian LM, et al. (1999) Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy. Archives of Neurology 56: 1254-1261.
|